Long-term Efficacy and Safety of Combined Topical Antiglaucoma Therapy-Timolol & Unoprostone vs. Betaxolol & Unoprostone-
|
Accession number;04A0081338
|
| Title;Long-term Efficacy and Safety of Combined Topical Antiglaucoma Therapy-Timolol & Unoprostone vs. Betaxolol & Unoprostone- |
| Author;
OTAKE YUICHIRO
(Sch. of Med., Keio Univ.)
TANINO TOMIHIKO
(Sch. of Med., Keio Univ.)
KIMURA ITARU
(Sch. of Med., Keio Univ.)
MASHIMA YUKIHIKO
(Sch. of Med., Keio Univ.)
OGUCHI YOSHIHISA
(Sch. of Med., Keio Univ.)
|
Journal Title;Journal of Japanese Ophthalmological Society
|
Journal Code:Z0666A
|
ISSN:0029-0203
|
|
VOL.108;NO.1;PAGE.23-28(2004)
|
| Figure&Table&Reference;FIG.6, TBL.3, REF.33 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Purpose: To evaluate long-term efficacy and safety of treatment combining topical .BETA.-blockers and isopropyl unoprostone in primary open-angle glaucoma and normal-tension glaucoma patients. Methods: A prospective, open-label, parallel-group clinical comparison trial was performed to evaluate efficacy and safety of treatment combining 0.5% betaxolol and 0.12% isopropyl unoprostone (B&U) or 0.5% timolol and 0.12% isopropyl unoprostone (T&U). Forty eyes of 40 patients, which were matched in the aging and the stage of glaucomatous visual field defect, were studied. Twenty patients were treated with B&U and the other twenty patients with T&U twice daily for 24 months. Goldmann intraocular pressure (IOP), Humphrey automated perimetry, blood pressure, heart rate, and peak flow were done every six months in each group. Results: In the B&U treatment group, mean IOP was 21.2 mmHg at baseline and 18.3 mmHg (p<0.005) after 2 years, and in the T&U treatment group it was 21.1 mmHg at baseline and 17.9 mmHg (p<0.001) after 2 years. The cases in which MD value decreased over 2 dB were one in the B&U treatment group and three in the T&U treatment group. The average MD value was significantly improved from -7.40 dB to -5.90 dB after 2 years with B&U treatment (p<0.05), but there was no difference with the T&U treatment. None of the patients stopped combined therapy because of side effects, though heart rate was significantly reduced only in T&U treatment group. Conclusion: Both combined treatments were effective for IOP reduction in glaucoma patients, and the data from the B&U treatment group suggested that B&U was more effective in maintaining visual field than T&U. (author abst.) |
|
|
|
Related Articles;
|
|
|
